Fentanyl Intranasal for Retinopathy of Prematurity Screening in Preterm Infants

Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorMarsha Campbell-Yeo

About this trial

The goal of this clinical trial is to learn whether intranasal fentanyl (a pain medicine given as a nasal spray) can reduce pain and is safe to use during routine eye examinations for retinopathy of prematurity (ROP) in preterm infants. ROP is an eye condition that can affect babies born too early and requires regular eye examinations. The main questions this study aims to answer are: Does intranasal fentanyl lower pain during ROP screening? Is intranasal fentanyl safe for preterm infants? Researchers will compare intranasal fentanyl with a placebo (a saltwater spray that contains no medicine) to determine whether the medicine lowers pain during ROP screening.

Participants will receive either intranasal fentanyl or placebo before their routine ROP eye examination, in addition to the standard comfort measures normally used during the procedure. Researchers will measure participants' pain and monitor their heart rate, oxygen levels, and any side effects during and after the examination.

Eligibility criteria

Qualifiers

Preterm infants born ≤31 weeks gestational age and/or with birth weight <1250 g

Scheduled to undergo routine retinopathy of prematurity (ROP) screening as part of standard NICU care

Clinically stable at the time of screening, defined as not requiring acute resuscitative support (no bag-mask ventilation, intubation, or chest compressions within the preceding 24 hours) and maintaining stable cardiorespiratory parameters on baseline respiratory support

Written informed consent obtained from a parent or legally authorized representative

Disqualifiers

Congenital anomalies or conditions affecting the nasal passages that would interfere with intranasal drug administration

Receipt of systemic opioids, benzodiazepines, barbiturates, or other sedative/analgesic medications within 24 hours prior to the ROP examination

Known hypersensitivity or prior adverse reaction to fentanyl

Trial design

Treatments tested in this trial

  • Fentanyl Citrate (Intranasal)
  • Normal Saline (Placebo, Intranasal)

Treatment groups

58 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Marsha Campbell-Yeo

Lead sponsor

IWK Health Centre

Sponsor institution

Canadian Institutes of Health Research (CIHR)

Collaborator

Dalhousie University

Collaborator

IWK Health Centre

Collaborator